scholarly journals Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management

Hepatology ◽  
2006 ◽  
Vol 44 (4) ◽  
pp. 1039-1046 ◽  
Author(s):  
Stephen H. Caldwell ◽  
Maureane Hoffman ◽  
Ton Lisman ◽  
B. Gail Macik ◽  
Patrick G. Northup ◽  
...  
Keyword(s):  
Liver Disease ◽  
Critical Assessment ◽  
Coagulation Disorders ◽  
Current Management

Hepatocellular Carcinoma in Alcoholic Liver Disease: Current Management and Recent Advances

2016 ◽  
Vol 11 (3) ◽  
pp. 238-252
Author(s):  
Giovanni Galati ◽  
Chiara Dell'Unto ◽  
Umberto Vespasiani-Gentilucci ◽  
Antonio De Vincentis ◽  
Paolo Gallo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Alcoholic Liver Disease ◽  
Current Management ◽  
Recent Advances

scholarly journals Current management of NAFLD

2016 ◽  
Vol 89 (1) ◽  
pp. 19-23 ◽  
Author(s):  
Mihai Alexandru Munteanu ◽  
Georgiana Anca Nagy ◽  
Petru Adrian Mircea
Keyword(s):  
Liver Disease ◽  
General Population ◽  
Pharmacological Therapy ◽  
Lifestyle Changes ◽  
Current Management ◽  
Alcoholic Fatty Liver ◽  
Risk Of Death ◽  
Increased Risk ◽  
Diet And Lifestyle ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries. It affects about 1 billion individuals worldwide. While people with simple steatosis have no higher risk of death than the general population, people with non-alcoholic steatohepatitis are at increased risk of death compared to general population. Current management for NAFLD includes diet and lifestyle changes, management of underlying metabolic risk factors and pharmacological therapies. The objective of therapy is to prevent the complications. The problem with dietary and lifestyle interventions is that they are hard to implement. Compliance is the key. Until now, there is still no approved drug for the treatment of NAFLD. Insulin resistance is the main target of pharmacological therapy, but the question that we ask ourselves as physicians is who should receive medical treatment among NAFLD patients and for how long.

scholarly journals Current management of non-alcoholic fatty liver disease

2016 ◽  
Vol 62 (9) ◽  
pp. 872-878 ◽  
Author(s):  
QUELSON COELHO LISBOA ◽  
SILVIA MARINHO FEROLLA COSTA ◽  
CLÁUDIA ALVES COUTO
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Lifestyle Modification ◽  
Hepatic Inflammation ◽  
Current Management ◽  
Multicenter Studies ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

SUMMARY Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic accumulation of lipid in patients who do not consume alcohol in amounts generally considered harmful to the liver. NAFLD is becoming a major liver disease in Eastern countries and it is related to insulin resistance and metabolic syndrome. Treatment has focused on improving insulin sensitivity, protecting the liver from oxidative stress, decreasing obesity and improving diabetes mellitus, dyslipidemia, hepatic inflammation and fibrosis. Lifestyle modification involving diet and enhanced physical activity associated with the treatment of underlying metabolic are the main stain in the current management of NAFLD. Insulin-sensitizing agents and antioxidants, especially thiazolidinediones and vitamin E, seem to be the most promising pharmacologic treatment for non-alcoholic steatohepatitis, but further long-term multicenter studies to assess safety are recommended.

Improvement Of Plasmatic Coagulation In Patients With Liver Disease To Enable Necessary Diagnostic And Therapeutic Steps

1981 ◽  
Author(s):  
G E Vogel ◽  
S Tuchtenhagen ◽  
Ch Komm ◽  
A Oberdorfer
Keyword(s):  
Liver Disease ◽  
Esophageal Varices ◽  
Liver Diseases ◽  
Bleeding Complication ◽  
Coagulation Factors ◽  
Coagulation Disorders ◽  
Chromogenic Substrates ◽  
At Iii ◽  
Plasmatic Coagulation ◽  
Plasma Activity

Specific plasmatic concentrations of coagulation factors are necessary in endoscopic treatment e.g. slerosis of esophageal varices. Thrombotest of 35 to 40% is necessar. To correct with factor concentrates and fibrinogen is dangerous in cause of pushing DIC (disseminated intravascular coagulation). The substitution of the inhibitor AT III which is succeeded from prothrombin concentrates and fibrinogen avoid fearful consumption reactions. The AT III plasma activity was measured by chromogenic substrates in citric plasma. In 5 patients (2 female, 3 male- age 19-67) the diminished AT III-levels were increased to the normal value of 80%. After normalization of the inhibitors prothrombin complexes and if necessary fibrinogen were substituted. It was seen an assessable improvement of the plasmatic coagulation which depends on the unit concentration of the substituted factors. In the improved coagulation situation 2 laparoscopies and 3 slerosis of esophageal varices could be done without any bleeding complication.Patients with liver diseases and coagulation disorders who were unsuitable for endoscopic and surgical treatment can be treated with this concept.

Coagulation Disorders in Liver Disease

2002 ◽  
Vol 22 (1) ◽  
pp. 083-096 ◽  
Author(s):  
Lucio Amitrano ◽  
Maria A. Guardascione ◽  
Vincenzo Brancaccio ◽  
Antonio Balzano
Keyword(s):  
Liver Disease ◽  
Coagulation Disorders
Sign in / Sign up

Export Citation Format

Share Document